Article Figures & Data
Figures
- Figure 1.
Induction of cytoxicity and inactivation of EGFR/NF-κB was found in regorafenib combination with cisplatin in A549 cells. A549 cells were treated with (A) 0-30 μM regorafenib, (B) 0-25 μM cisplatin, (C) 10 μM regorafenib combined with 0-25 μM cisplatin, (D) 0-5 μM QNZ, (E) 1 μM QNZ combined with 0-25 μM cisplatin and (F) 10 μM erlotinib combined with 0-25 μM cisplatin for 48 h and assayed by MTT. (G-H) The expression pattern and quantification results of EGFR and NF-κB phosphorylation are shown. a1p<0.05, a2p<0.01, a3p<0.005 vs. 0 μM of treatment; b2p<0.01, b3p<0.005 vs. 10 μM regorafenib, 1 μM QNZ or 10 μM erlotinib; c1p<0.05 vs. 15 μM cisplatin).
- Figure 2.
Synergistic activation of death receptor of apoptosis and mithochondria-dependent apoptosis were found in regorafenib combined with cisplatin in A549 cells. A549 cells were treated with 10 μM regorafenib, 15 μM cisplatin and their combination for 48 h. The activation patterns and quantification results of (A) caspase-3, (B) caspase-8, and (C) caspase-9 were assayed by flow cytometry. (D) AIF nuclear translocation pattern of each group is displayed. a2p<0.01, a3p<0.005 vs. 0 μM of treatment; b3p<0.005 vs. 10 μM regorafenib; c1p<0.05, c2p<0.01, c3p<0.005 vs. 15 μM cisplatin scale bar = 50 μM.
- Figure 3.
Suppression of metastasis effect was found in regorafenib combined with cisplatin in A549 cells. A549 cells were treated with 10 μM regorafenib, 15 μM cisplatin and their combination for 48 h. (A) Migration and invasion pattern of A549 after different treatments are displayed. The quantification of (B) migration area and (C) invasion area after different treatments are presented. (D) The metastasis related proteins expression pattern and quantification bar chart are displayed. a2p<0.01, a3p<0.005 vs. 0 μM of treatment; b2p<0.01, b3p<0.005 vs. 10 μM regorafenib; c2p<0.01 vs. 15 μM cisplatin scale bar = 100 μM.
